Patents by Inventor Timothy R. Mosmann

Timothy R. Mosmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treatment using cytokine synthesis inhibitory factor
    Patent number: 6312680
    Abstract: Mammalian genes and proteins, designated cytokine synthesis inhibitory factors (CSIFs now known as Interleukin-10 (IL-10)), are provided which are capable of inhibiting the synthesis of cytokines associated with delayed type hypersensitivity responses, and which, together with antagonists, are useful in treating diseases associated with cytokine imbalances, such as leishmaniasis and other parasitic infections, and certain immune disorders including MHC associated autoimmune diseases caused by excessive production of interferon-&ggr;.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 6, 2001
    Inventors: Timothy R. Mosmann, Kevin W. Moore, Martha W. Bond, Paulo J. M. Vieira
  • Binding compositions specific for interleukin-10
    Patent number: 6239260
    Abstract: Mammalian genes and proteins, designated cytokine synthesis inhibitory factors (CSIFs) or interleukin 10 (IL-10), as well as antibodies which specifically bind IL-10, are provided. These proteins, and antibodies, may be used to treat various disease states associated with cytokine imbalances.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 29, 2001
    Assignee: Schering Corporation
    Inventors: Timothy R. Mosmann, Kevin W. Moore, Martha W. Bond, Paulo J. M. Vieira
  • Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
    Patent number: 6217857
    Abstract: Mammalian genes and proteins, designated cytokine synthesis inhibitory factors (CSIF's, now known as Interleukin-10 (IL-10)), are provided which are capable of inhibiting the synthesis of cytokines associated with delayed type hypersensitivity responses, and which, together with antagonists, are useful in treating diseases associated with cytokine imbalances, such as leishmaniasis and other parasitic infections, and certain immune disorders including MHC associated autoimmune diseases caused by excessive production of interferon-&ggr;.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 17, 2001
    Assignee: Schering Corporation
    Inventors: Timothy R. Mosmann, Kevin W. Moore, Martha W. Bond, Paulo J. M. Vieira
  • Methods of treatment using antagonists of cytokine synthesis inhibitory factor
    Patent number: 6207154
    Abstract: Mammalian genes and proteins, designated cytokine synthesis inhibitory factors (CSIFs, now known as Interleukin-10 (IL-10)), are provided which are capable of inhibiting the synthesis of cytokines associated with delayed type hypersensitivity responses, and which, together with antagonists, are useful in treating diseases associated with cytokine imbalances, such as leishmaniasis and other parasitic infections, and certain immune disorders including MHC associated autoimmune diseases caused by excessive production of interferon-&ggr;.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 27, 2001
    Assignee: Schering Corporation
    Inventors: Timothy R. Mosmann, Kevin W. Moore, Martha W. Bond, Paulo J. M. Vieira
  • Nucleic acids encoding cytokine synthesis inhibitory factor (Interleukin-10)
    Patent number: 6018036
    Abstract: Mammalian genes and proteins, designated cytokine synthesis inhibitory factors (CSIFs, now known as Interleukin-10 (IL-10)), are provided which are capable of inhibiting the synthesis of cytokines associated with delayed type hypersensitivity responses, and which, together with antagonists, are useful in treating diseases associated with cytokine imbalances, such as leishmaniasis and other parasitic infections, and certain immune disorders including MHC associated autoimmune diseases caused by excessive production of interferon-.gamma..
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: January 25, 2000
    Assignee: Schering Corporation
    Inventors: Timothy R. Mosmann, Kevin W. Moore, Martha W. Bond, Paulo J. M. Vieira
  • Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
    Patent number: 5231012
    Abstract: Mammalian genes and proteins, designated cytokine synthesis inhibitory factors (CSIFs) (now known as interleukin -10), are provided which are capable of inhibiting the synthesis of cytokines associated with delayed type hypersensitivity responses, and which, together with antagonists, are useful in treating diseases associated with cytokine imbalances, such as leishmaniasis and other parasitic infections, and certain immune disorders including MHC associated autoimmune diseases caused by excessive production of interferon-.gamma..
    Type: Grant
    Filed: July 20, 1992
    Date of Patent: July 27, 1993
    Assignee: Schering Corporation
    Inventors: Timothy R. Mosmann, Kevin W. Moore, Martha W. Bond, Paulo J. M. Vieira
  • T cell activation markers
    Patent number: 5136022
    Abstract: A polypeptide designated H400 and its encoding nucleic acid are provided as markers specific for activated human T cells. Activated T cells are detected immunochemically by monoclonal antibodies specific for H400 or its immunogenic peptides. Activated T cells are also detected by nucleic acid probes directed to messenger RNA encoding the H400 protein.
    Type: Grant
    Filed: January 14, 1991
    Date of Patent: August 4, 1992
    Assignee: Schering Corporation
    Inventors: Keith D. Brown, Timothy R. Mosmann, Gerard Zurawski, Sandra M. Zurawski